Psychiatry & Neurology Doctors in Knoxville, TN Accepting Medicare

103 Psychiatry & Neurology doctors found. Showing 101 - 103

Alok Sachdeva, M.D. Psychiatry & Neurology - Sleep Medicine Medicare: Accepting Medicare Assignments Practice Location: 1128 E Weisgarber Rd Ste 201, Knoxville, TN 37909 Phone: 865-909-0744    Fax: 833-908-2120

Mr. Kris D Houser, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 212 S Peters Rd, Ste 201, Knoxville, TN 37923 Phone: 865-539-1001

David Michael Greer, MD Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 5731 Lyons View Pike, Suite 115, Knoxville, TN 37919 Phone: 865-776-1023

News Archive

Textile cooling pads to prevent neurological damage after successful resuscitation

Textile cooling pads are to be used in future to prevent neurological damage after successful resuscitation. The system developed by scientists from the Hohenstein Institute in Bönnigheim requires no electric power, making it ideal especially for first aid in case of cardiac arrest.

Data from high-quality registries to be considered in benefit assessment of drugs

Particularly in the case of accelerated drug approvals and drugs for rare diseases (orphan drugs), the evidence available at the time of market access is often insufficient for the early benefit assessment of drugs.

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

Shamir first-quarter revenue up 18.2% to $40.1 million

Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the first quarter ended March 31, 2010.

Read more Medical News

› Verified 5 days ago

• 1
• 2
• 3
• 4
• 5
• 6(current)